Smoking selects mutants

In the October 24 Proceedings of the National Academy of Sciences Rodin and Rodin propose that smoking leads to increased lung cancer not by causing more mutations, but by selecting for those mutations that do arise (Proc Natl Acad Sci USA 2000, 97:12244-12249). They take advantage of an increase in p53 mutational data in nonsmokers and find, for example, that the frequency of silent mutations in p53 is identical between smokers and non-smokers. In contrast, twice as many lung cancers from smoke

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

In the October 24 Proceedings of the National Academy of Sciences Rodin and Rodin propose that smoking leads to increased lung cancer not by causing more mutations, but by selecting for those mutations that do arise (Proc Natl Acad Sci USA 2000, 97:12244-12249). They take advantage of an increase in p53 mutational data in nonsmokers and find, for example, that the frequency of silent mutations in p53 is identical between smokers and non-smokers. In contrast, twice as many lung cancers from smokers have a defective p53 as compared to lung cancers from non-smokers. Rodin and Rodin suggest that the more often that smoking-related stresses such as hypoxia induce p53-related cell cycle arrest or apoptosis, the higher the probability that a p53 mutant cell will be selected. If true, this would mean that eliminating specific carcinogens from cigarettes would have little effect on the occurrence of lung cancer.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • William Wells

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide